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INTRODUCTION
Colonizing Candida may gain access to the circulation and cause invasive bloodstream infection or organ diseases, including hepato-splenic candidiasis and candida nephritis [1] . Invasive candidiasis typically occur in hemato-oncology patients and in those with long-term therapy at intensive care unit [2, 3] . In addition, patients with chronic granulomatous disease or other primary defects of phagocytic cell function, as well as those with quantitative deficiency of the phagocytic cell pool also predispose to invasive candidiasis [4, 5] . In contrast, superficial or chronic mucocutaneous
The Evolving View of IL-17-Mediated Immunity in Defense against Mucocutaneous  candidiasis (CMC) occurs at body surfaces as vulvovaginal, oropharyngeal or esophageal candidiasis [6] [7] [8] . Several primary immunodeficiency disorders (PIDs) typically characterized by CMC and impaired IL-17-mediated immunity have been identified recently [9] . CMC in such patients may be part of a complex clinical phenotype exemplified by dominant negative signal transducer and activator of transcription (STAT)3 deficiency, interleukin (IL)-12Rβ1 and IL-12p40 deficiencies, and autoimmune polyendocrine syndrome (APS) type 1 [10] [11] [12] [13] . In a subgroup of PIDs, predisposition to superficial candidiasis may be the only or the dominant characteristic of the underlying genetic disorder (CMC disease, CMCD) [9] . The first CMCD was described in 2011 by two groups reporting on 21 unrelated families and 61 patients carrying germline missense mutation in the coiled-coil domain (CCD) of STAT1 [14, 15] . One of these groups also reported on impaired differentiation of naïve CD4+ T cells into IL-17+ lymphocytes due to gain of function (GOF) and gain of phosphorylation of STAT1 in a large number of patients with CMCD [14] . Subsequently, STAT1 GOF mutation associated with CMC was found by several groups [16] [17] [18] [19] [20] [21] . Primary genetic defects of the IL-17 cytokine-IL-17R coupling and IL-17R signaling were also reported as causes of CMCD [22, 23] . In particular, autosomal dominant IL-17F deficiency, autosomal recessive IL-17RA deficiency, and signaling defect due to mutation in the gene of nuclear factor kappa B (NF-κB) activator (ACT1) were described. In this review, we discuss recent developments that have increased our understanding of the immunological and genetic basis of CMC. Molecular mechanisms that may be involved in the unique and exceptional tropism of Candida, especially Candida albicans, at the mucosal epithelium will be discussed. Effector functions of CD4+IL17+ T cells will be reviewed in the context of host defense against infection by Candida at mucosal surfaces. Finally, we will discuss inborn errors of IL-17-mediated immunity that may lead to CMC in humans.
Candida as a Unique Fungal Commensal in Humans
Candida, Aspergillus and Cryptococcus are the three major opportunistic fungal species. Candida, especially C. albicans stands out as the most common fungal pathogen in humans. In healthy individuals, C. albicans adheres to the mucosal epithelium and skin which is usually symptomless as an established commensalism [24, 25] . In patients with impaired anticandidal host defense, however, these fungi may cause persistent and recurrent superficial infection and epithelial cell damage which may be recalcitrant to therapy. The precise mechanism of commensalism by C. albicans is not completely understood [25, 26] . To establish colonization Candida must have developed the unique ability to adhere to epithelial cells so that to avoid being washed away by food and mucosal secretion. Candida should also be able to compete with other colonizing agents like bacteria in the gastrointestinal tract. Furthermore, Candida should be able to survive a large array of host immune and non-immune defenses at mucosal surfaces. Although the commensal phase itself is generally considered harmless, it may develop into CMC and invasive candidiasis, which is referred to as the pathogenic phase of C. albicans. Symptomatic damage of the mucosal epithelium is characteristic for the pathogenic phase, but asymptomatic damage may also occur during the commensal phase [26, 27] .
Candida species "appear to know something" that remains to be elucidated by scientists searching for a better understanding of host defense against these fungi. It is intriguing that among the Candida species only a few colonize the mucocutaneous surfaces and associate with human disease [27, 28] . C. albicans may especially closely associate to humans in contrast to other fungi. Commensal colonization of Candida is a remarkable condition because the vast majority of both CMC and invasive candidiasis are of endogenous origin [28] . Invasive candidal disease may be caused by various non-albicans Candida like C. glabrata, C. tropicalis and C. parapsilosis. However, C. albicans is the most common species isolated from patients with CMC. One possible explanation may be that C. albicans, in contrast to non-albicans species, grow hyphae that invade and penetrate epithelial cells more aggressively than yeasts. Experimental data suggest that formation of hyphae may be related to virulence of C. albicans and possibly C. dubliniensis which is also known to form hyphae [29] . Major Candida adhesins including hyphal wall protein (Hwp) 1 that binds trans-glutaminase, and the agglutinin-like sequence (Als) 3 that binds host cell cadherin may play a role for epithelial binding [30, 31] . That, Candida adhesins may be important to establish epithelial damage is supported by the observation that deletion of genes encoding for Hwp1 or Als3 result in remarkable decrease of adhesion to epithelial cells. Other adhesins on hyphae may recognize arginine-glycine-aspartic acid (RGD) sequences on epithelial cells and several extracellular matrix proteins [32] . Integrin-like protein (INT) 1 may recognize RGD-containing proteins. This candidal adhesin is homologous to mammalian integrins and itself contains an RGD site that may be recognized by integrins on human cells, facilitating further the adhesion of Candida to the cell surface [32] . These findings provide further explanation for the unique symbiosis of Candida with humans and the tropism of these fungi to mucosal epithelium. Whether Candida remains a silent and innocent colonizer or becomes an aggressive mucosal or invasive pathogen depends largely on the ability of the host to mount an efficient IL-17-mediated effector immunity.
Th17 Cells as Major Players of Host Defense against Candida at Mucosal Surfaces
A subset of CD4+ helper T cells typically produce IL-17A-type cytokines including IL-17A-E and IL-22 and are referred to as Th17 cells or CD4+IL-17+ T cells [33] . Th17 cytokines are important for the prevention of infection with Candida colonizing the mucocutaneous surfaces [9] (Fig. 1) . The differentiation, expansion and maintenance of human IL-17-producing T cells are induced by a set of cytokines, including IL-1β, IL-6, IL-21, IL-23 and probably TGF-β, and transcription factors such as STAT3, retinoic acid-related orphan receptor (ROR)-γ t and interferon regulatory factor 4 [33] [34] [35] [36] [37] (Fig. 1) . IL-17A is produced not only by conventional CD4+IL-17+ T helper cells, but also by γ δ T cells and innate lymphoid cells [38, 39] .
Over the past decade our understanding of IL-17+ T lymphocyte-mediated immunity has paralleled with a better understanding of host defense against Candida of body surfaces. The discovery that CD4+ T cell may be induced by IL-1β and IL-6 toward a CD4+ T cell subset producing IL-17 (CD4+IL17+ cells) opened a new avenue of intensive research into the pathology of various inflammatory conditions and host defense mechanisms against Candida [40] .
Induction of Th17 Differentiation by Pattern Recognition Receptors
The differentiation of naïve CD4+ T-helper cells into IL-17-producing T cells and the development of effective mucosal immunity against fungi may be initiated by binding of Candida to innate immune cells via pattern recognition receptors (PRRs). These receptors including toll-like receptor (TLR) 2, TLR4, the macrophage mannose receptor (MR), dectin-1, dectin-2 and the macrophage-inducible C-type lectin (MINCLE) may bind pathogen-associated molecular patterns such as fungal mannoproteins and β-glucans [41] [42] [43] [44] [45] .
Recognition of mannoproteins and glycans by PRRs have been implicated to play a role in host defense against Candida and innate defense mechanisms were proposed to shape the adaptive responses by promotion of skewing CD4+ T cells into Th17 lineage [42, 45, 46] . TLR2 and TLR4 may bind Candida but it was poorly defined how The Evolving View of IL-17-Mediated Immunity in Defense against Mucocutaneous  Adapted from [9, 37] .
these interactions alter host defense mechanisms [41] . Contradicting data were reported in mice and humans regarding the role of TLR-mediated immunity to Candida and it appears that myeloid differentiation factor (MyD) 88 deficiency do not predispose humans, in contrast to mice to infections by this fungal pathogen [47, 48] . For example, TLR4
−/− mice exhibited increased susceptibility to invasive candidiasis, whereas TLR2
−/− mice were more resistant to Candida [49, 50] . The macrophage MR, one of the best characterized C-type lectin receptor (CLR) was the first membrane receptor implicated in the recognition of Candida yeasts by human macrophages [43, 44, [51] [52] [53] . Monocyte-derived human macrophages (MDM) ingested and killed unopsonized Candida blastoconidia but both phagocytosis and killing of unopsonized yeasts were slower than those of serum-opsonized Candida [42] . Furthermore, unopsonized Candida evoked negligible release of toxic oxygen radicals compared to the robust generation of these agents by serum-opsonized yeasts [42] . These data suggested that the macrophage MR-mediated uptake of Candida yeast could play a role in elimination of these fungi in tissue environments which are poor in opsonising serum such as the subepithelial compartment and body surfaces. Human blood mononuclear cells could be induced to differentiate into IL-17+ cells by mannan but not by β-glucan or chitin indicating a role for the MR in shaping IL-17-mediated immunity [46] . In addition, MR-dependent production of IL-17 by cells from dectin-1 deficient patients was reported suggesting the role of the MR but not of dectin-1 in the generation of IL-17 cellular responses [46] . Thus, the role that dectin-1 may play in defense against Candida in mice remains to be further defined in humans.
Dectin-2 receptors primarily recognise N-linked mannan exposed on the surface of Candida and in particular, recognise hyphae rather than yeasts and may be more relevant innate immune sensors in recognition of Candida than dectin-1 [54] . We believe that multiple cell-fungal interactions may be required to initiate and mount predominantly Th17 differentiation and the relative role of various PRRs in this complex immunopathological process should be the focus of further research. For example, primary deficiency of caspase recruitment domain (CARD) 9 involved in signaling by different lectin receptors was described in a large Iranian family and was proposed to predispose patients to CMC [55] . However, two of the eight patients reported in this family also had invasive candidiasis and two of the patients had no proven candidal disease. More intriguingly, several patients with invasive infections caused by dermatophytes but not Candida have been reported recently [56] [57] [58] . Thus, the expanding spectrum of clinical phenotype in patients with CARD9 deficiency makes a direct relationship between CMC and this PID to be further elucidated.
Inborn Errors of Th17-mediated Immunity in Humans
Experiments in nature suggest that patients with germ line mutations in STAT3 resulting in the complex clinical phenotype of hyper-IgE syndrome (HIES), AIRE mutation causing APS-1 and IL12Rβ1 deficiency causing increased susceptibility to atypical Mycobacteria and Salmonella are also susceptible to CMC [9] [10] [11] [12] [13] . Patients with these PIDs present with an impaired differentiation of IL17+CD4+ T cells (HIES and IL12Rβ1 deficiency) or increased production of anti-IL-17 antibodies (APS-1). STAT1 GOF mutation was also reported to interfere with Th17 differentiation and turned out to be the most common cause of isolated CMC (CMC disease, CMCD) [14] [15] [16] [17] [18] [19] [20] [21] . Sporadic cases of CMCD caused by germ line mutations of IL17F, IL17RA and ACT1 and characterized by impaired stimulus-response coupling and signaling via the IL17R were also reported [22, 23] .
The milestone discovery of the genetic cause of autosomal dominant HIES HIES (Job's syndrome) is a complex PID characterized by skin and lung infections caused predominantly by Staphylococcus aureus and C. albicans, pneumatocele formation, severe eczema and extreme elevation of serum IgE [10, [59] [60] [61] . Distinctive facial features, hyperextensibility of the joints, cranial synostosis, scoliosis, abnormal dentition and predisposition to pathological fractures add to the multisystem phenotype of HIES. Staphylococcal skin abscesses typically fail to demonstrate erythema and warmth, and hence are called "cold abscesses" [59] .
The first breakthrough in our understanding of the role of IL-17-mediated immunity in host defense against Candida of mucocutaneous surfaces was achieved by the discovery of the genetic basis of HIES. In 2007, two independent groups reported mutation in STAT3 as a major cause of autosomal dominant (AD) and sporadic HIES [62, 63] . Mutations were localized in either the DNA-binding domain (DBD) or the SH2 domain of STAT3 but later were described throughout the gene and in different ethnic groups [64, 65] . Severe Th17 cell depletion was also reported in AD and sporadic HIES patients with STAT3 dominant negative mutation [66] [67] [68] . This observation was in con- The (Fig. 1) .
STAT3 is a transcription factor involved in signaling for a variety of cytokines, hormones and growth factors which may explain the complex clinical phenotype and multiple organ involvement in HIES patients [69, 70] . STAT3 plays important roles in maturation, differentiation and function of T and B cells [71, 72] . In addition to its involvement in Th17 cell differentiation, induction of CD4+ T cells toward the follicular helper T cell lineage may also depend on STAT3 [73] . Patients with dominant negative STAT3 mutation present with a decreased number of central memory CD4+ and CD8+ lymphocytes and an increased number of naïve T cells [74] . Due to this memory, T cell defect patients with HIES are predisposed to develop varicella zoster virus reactivation and prolonged Epstein-Barr virus viremia.
The impaired IL-17+ T cell differentiation and function may be a plausible explanation for the susceptibility of HIES patients to CMC [9] . However, such patients are also susceptible to infections by pyogenic bacteria, especially S. aureus causing recurrent skin and lung infections [37, 60, 61] . Alternative mechanisms responsible for the unique vulnerability to infection of the skin, mucous membranes and the lung in HIES patients may exist. In patients with oropharyngeal thrush a significant impairement in salivary antimicrobial proteins such as β-defensin 2 was found [75, 76] . The defective salivary gland activity may be related to the reduced candidacidal activity of saliva and Candida colonization of the mucosa at least in the oropharynx. In addition, defective responses of keratinocytes and bronchial epithelial cells to IL-17 was reported as a possible additional mechanism responsible for the impaired host defense to Candida by HIES patients [68] . Cells from HIES patients were more dependent than from healthy controls on the synergistic effect of Th17-derived cytokines and classical proinflammatory cytokines such as IL-1β in their production of chemokines and antimicrobial peptides.
Discovery of STAT1 GOF mutation as the most common cause of CMC
The signaling pathway triggered by the engagement of interferons (IFN-γ , IFN-α/β) and IL-27 with their specific cell surface receptors have been extensively studied and provided knowledge of the intracellular machinery that include a predominant activation of STAT1. Loss of function (LOF) mutations in STAT1 were reported to associate with various infections through mechanisms involving impaired IFN-γ and IFN-α/β immunity [71, 77] . Complete and partial recessive mutations in STAT1 were described to result in an increased susceptibility to mycobacterial and viral diseases because of impaired responses to both IFN-γ and IFN-α/β [77] . In contrast, heterozygous dominant negative mutation in STAT1 cause susceptibility to mild mycobacterial infection because of impaired response to IFN-γ but not to IFN-α/β. Recently heterozygous GOF mutation causing impaired development of IL-17+ T cells from CD4+ T cells were described in patients with CMC [14, 15] . These GOF mutations resulted in increased phosphorylation, DNA binding, transactivation, and interaction with protein inhibitor of activated STAT (PIAS), and decreased dephosphorylation of STAT1 [14, 78] . Thus, the poor development of IL-17+ T cells, and as a consequence CMC may involve increased responses to IFN-γ , IFN-α/β and IL-27, which are STAT1-dependent repressors of IL-17-producing cells. STAT1 GOF mutation was first discovered by whole-exome sequencing in a Ukrainian patient with CMCD [14, 35] . CCD and DBD mutations were subsequently found in a large number of patients in other kindreds [14] [15] [16] [17] [18] [19] [20] [21] . Over the past few years, GOF mutations of STAT1 have been proved to be the most common etiology of CMC. Heterozygous dominant STAT1 GOF mutation may lead to stronger cellular responses to STAT1-dependent IL-17 inhibitors Copyright C Informa Healthcare USA, Inc.
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(IFN-α/β, IFN-γ and IL-27) [14] . This would account for the impaired IL-17+ T-cell development with an impact on IL-17+ T cell-mediated antifungal responses.
Infectious etiologies which were also described in association with STAT1 GOF mutation include Histoplasma capsulatum, Coccidioides immitis, Apophysomyces trapeziformis, orf virus, Penicillium marneffei and Fusarium solani [17, [78] [79] [80] [81] [82] . Patients with STAT1 GOF mutations may display herpes reactivation diseases in addition to CMCD [17] . The recurrent herpes virus disease observed in some patients with such mutations may be due to the impaired development and maintenance of central memory T cells, as in patients with heterozygous STAT3 mutations and AD HIES [83] .
Deficient functioning of the IFN-γ /IL-12 pathway was found to associate with invasive infection by dimorph endemic fungi like Histoplasma capsulatum and Coccidioides immitis [84, 85] . Five patients with STAT1 GOF mutation were also identified with invasive histoplasmosis and CMC (3 patients) and coccidioidomycosis without CMC (2 patients) [78] . The heterozygous missense mutations affecting the CCD or DBD of STAT1 resulted in lower STAT1 methylation, enhanced STAT1/protein inhibitor of activated STAT1 (PIAS) association, increased IFN-γ -induced gene expression, and impaired responses to IFN-γ restimulation. This report and other studies suggested the intriguing possibility of functional overlap of GOF and LOF mutations of STAT1.
STAT1 GOF mutation has been identified in a 24-year-old male patient with disseminated mucormycosis caused by Apophysomyces trapesiformis [79] . This patient never had CMC or autoimmunity and he had no predisposing condition to mucormycosis, such as penetrating trauma, diabetes mellitus or hemochromatosis. Thus, A. trapesiformis and other members of the Mucorales species may cause infections in patients with STAT1 GOF mutation. Mucormycosis may be a heralding infectious manifestation of this genetic disorder before the occurrence of CMC.
A 34-year-old male patient with a previous history of recurrent and persistent candidiasis of the skin, nails, and mucosal surfaces starting at 2 years of age developed orf, a viral zoonotic disease, caused by Parapoxvirus [80] . Genetic analysis of this patient and his 6-year-old son who had been also suffering from CMC since birth, revealed heterozygous c.820G>A STAT1 mutation (R274W). This mutation was previously found to result in STAT1 GOF including enhanced phosphorylation and DNAbinding, and impaired differentiation of CD4+ T cells into IL-17+ cells [14, 17] . In contrast to other patients carrying the R274W mutation the index patient (but not his son) also had severe CD4 lymphopenia, low levels of IgG2 and IgG4 subclasses and recurrent bacterial pneumonias since 15 years of age. He was treated with regular IVIG infusions. The giant orf lesion on his hand was successfully cured with cidofovir. His disease course was complicated with Coombs positive hemolytic anemia, autoimmune hepatitis, hypothyroidism and pulmonary embolia. Despite successful hematopoietic stem cell transplantation performed at age 35 he died because of bleeding from an intracranial mycotic aneurism, a well-defined complication in patients with CMC [14, 21] . It remains unclear whether impaired Th17 immunity played any role in the development of orf in this patient. This report nevertheless raises the possibility that STAT1 GOF mutation may predispose to DNA viral disease other than recurrent varicella and HSV, described before in two patients also carrying the R274W mutation [17] .
STAT1 GOF mutation associated with CMC and invasive infection by Penicillium marneffey was reported in three Chinese patients [81] . Lymphocytes from two of these patients exhibited defective IFN-γ production upon stimulation with P. marneffey in vitro. The authors suggested that the combined primary defect in IFN-γ an IL-17 immune responses may be responsible for infection by this filamentous mold. This report further extends the spectrum of infections occurring in patients in STAT1 GOF The Evolving View of IL-17-Mediated Immunity in Defense against Mucocutaneous  mutation. It also suggests that the phenotypic expression of STAT1 GOF mutation may be wider than it was previously thought.
Another chronic fungal infections associated with a previously described STAT1 GOF mutation was found in a Chinese patients with infection by Fusarium solani [82] . This patient was free of CMC or invasive candidal disease. This report further confirms the possibility that STAT1 GOF mutation may predispose patients to a wide range of infections including various fungal disease.
Predisposition to CMC in patients with IL12Rβ1 and IL-12p40 deficiency IL-12 and IL-23 are heterodimeric cytokines compose of p35 and p19 subunits, respectively, and share a p40 subunit [86, 87] . The disulphide-bond 35 kD and 40 kD subunits of IL-12 produced primarily by professional antigen presenting cells bind to the IL-12 Rβ1/IL-12Rβ2 receptor complex [88] . IL-12 induces the production of IFN-γ by NK cells and T cells (Fig. 2) and drive CD4+ T cells to differentiate into Th1 phenotype [88, 89] . High-affinity binding of IL-12 to its receptor requires both IL-12Rβ1 and IL-12Rβ2 chains but gene expression studies suggested that the IL-12Rβ1 is primarily responsible for IL-12 binding whereas IL-12Rβ2 is mediating signaling [88] . On the other hand, the p19-p40 heterodimer of IL-23 also binds to IL-12Rβ1 but not to the β2 chain and uses its own receptor complex composed of IL-12Rβ1 and IL-23R on T cells and NK cells [90, 91] . IL-23 is a key cytokine to maintain expansion of CD4+IL17+ T cells that differentiate from naïve CD4+ cells upon exposure to IL-1β, IL-6 and IL-21 [33, 92] . Unsurprisingly, the functional impairment of IL-12Rβ1 was found to result in a wide range of infections caused predominantly by intracellular pathogens [93] [94] [95] [96] [97] [98] . T cells and NK cells from patients with IL-12Rβ1 mutation cannot respond to IL-12 or IL-23 because these cytokines bind to IL-12Rβ1 and these patients frequently develop CMC [11] . T cells and NK cells from patients with deficiency of the IL-12p40 subunit shared by IL-12 and IL-23 may also be susceptible to CMC because of the impaired maintenance of IL17+ T cells at mucosal surfaces. In contrast, patients with various genetic forms IFN-γ R deficiency do not display CMC [93] . Instead, they present with Mendelian susceptibility to mycobacterial disease.
Analyses of 156 patients with IL-12Rβ1 deficiency showed that 35 (23%) of such patients presented with clinical features of candidiasis [11] . Most patients were identified with recurrent and persistent CMC and candidiasis was the first documented clinical manifestation in 19 of 35 patients despite vaccination of 10 of these 19 patients with live bacille Calmette-Guérin vaccine. Most candidiasis episodes were mucocutaneous, oropharyngeal candidiasis being the most common, with esophageal, cutaneous and genital candidiasis also being recorded. In addition to mucosal or cutaneous fungal diseases, five episodes of invasive candidiasis affecting four patients were found. Intriguingly, in some patients the first episodes of candidiasis occurred before mycobacterial disease or salmonellosis were documented.
CMC was also observed in 3 (6.7%) of 49 patients with autosomal recessive IL12p40 deficiency [12] . One patient had invasive candidiasis and two presented with oral thrush. The immunological basis of the remarkably lower incidence of CMC in patients with IL-12p40 deficiency compared to that found in patients with IL-12Rβ1 deficiency is not completely understood.
Revealing germ-line IL17F, IL17RA and ACT1 mutations in patients with CMCD The binding of IL-17A and IL-17F to their receptors induces diverse signaling pathways and results in the secretion of antimicrobial peptides, tumor necrosis factor (TNF)-α, IL-6, IL-8, CXCL-1, CCL20, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [99] [100] [101] [102] . These cytokines and chemokines recruit and activate polymorphonuclear neutrophil granulocytes, providing protection against diverse infectious agents in the environment (Fig. 1) . Downstream signaling activated by IL-17R binding to its ligands include the adaptor protein ACT1 [100] [101] [102] [103] . IL-17A and IL-17F form heterodimers and homodimers and signal through a heteromeric receptor complex of two IL-17R chains: IL-17RA and IL-17RC (Fig. 3) [101, 103] . Receptor ligand coupling will subsequently result in recruitment of ACT1 [104] . Both IL-17R chains and ACT1 contain a conserved SEFIR domain and binding of these proteins occurs via homotypical interactions between their respective SEFIR domains (Fig. 3) . The E3 ubiquitine ligase TRAF6 binds then to ACT1 and mediates downstream signaling [103] [104] [105] . Ubiquitination of TRAF6 by ACT1 will trigger recruitment of TAK1 and the TAK1 binding partner molecules and induce NF-κB activation (Fig. 3) . ACT1 may also form a complex with the inducible kinase IKKi which will phosphorylate ACT1 and generate docking sites for the adaptors TRAF2 and TRAF5 [100, 102] .
The most compelling evidence that isolated CMC is truly a PID was provided by analyses of patients with recurrent or persistent Candida infections and AD IL-17F deficiency or autosomal recessive IL-17RA deficiency [22] . One of the published cases, a Copyright C Informa Healthcare USA, Inc.
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Moroccan boy, was born to consanguineous parents and was found to carry a homozygous c.850C > T mutation in the IL17RA gene, resulting in the creation of a premature stop codon (Q284X) in the part of the gene corresponding to the extracellular domain of the receptor. This mutation abolished responses to IL-17A and IL-17F, due to a complete loss of IL-17RA protein expression on the patient's cells. The parents and siblings of this patient were all healthy and heterozygous for this mutation [22] .
The other patients, from a multiplex Argentinean family, had a c.284C>T heterozygous mutation in the IL17F gene, predicting the replacement of serine residue with a leucine residue in position 65. This mutation was shown to be severely hypomorphic and dominant, as it affected the function of both homo-and heterodimers containing the mutant isoform, by impairing their binding to the receptor [22] . These observations clearly support the concept that CMC disease may occur as a result of inborn errors of IL-17-mediated immunity.
Biallelic missense mutation in the adaptor protein ACT1 and CMC in two siblings was reported [106] . The T536I mutation affected the SEFIR domain and abolished homotypic interaction between ACT1 and the IL-17R chains. This mutation also abolished responses of patients' fibroblasts to IL-17A and IL-17F and of T cells to IL-17E. In contrast to SEFIR-dependent interactions, binding of ACT1 to other proteins like CD40, heat shock protein (HSP) 70 and HSP90 remained intact.
CONCLUSION
C. albicans is a unique commensal at mucosal surfaces in humans and several PRRs of innate immune cells were implicated in binding Candida yeasts and hyphae. In particular, the role of PRRs in inducing Th17 cell differentiation from naïve CD4+ cells has been proposed but the precise mechanism of IL-17 induction has only been vaguely defined. Until the discovery of STAT3 dominant negative mutation causing severe defect of Th17 cell differentiation, our understanding of the mechanisms involved in host mucosal responses in humans to Candida was poor. Recent advances in our understanding of genetic etiologies of several PIDs such as STAT3 mutation in patients with AD and sporadic HIES, and STAT1 GOF mutation causing CMCD elucidated significantly our knowledge of anticandidal immunity of mucosal surfaces. Discoveries of IL17F, IL17RA and ACT1 mutations in association with CMCD enlightened further the mechanisms underlying CMC in patients with PIDs and have revealed that human IL-17+ T-cell immunity is critical for mucocutaneous host defense against Candida in natural conditions. More research is required to define precisely the mechanisms by which IL-17+ T cells contribute to the elimination of candidal and bacterial infections at body surfaces. Such studies should take into account the disease-modifying factors responsible for the severity and variability of the phenotypes of PIDs associated with IL-17+ T cell-mediated immune defects. 
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